Adalimumab in ulcerative colitis: Hypes and hopes

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Importance of the field: The advent of anti-TNF-α monoclonal antibodies has dramatically changed the management of inflammatory bowel diseases (IBD). Unlike Crohn's disease (CD), only one anti-TNF-α agent, infliximab, is currently approved for active moderate-to-severe ulcerative colitis (UC). Adalimumab is a fully human anti-TNF-α antibody that is effective and safe for the treatment of luminal and fistulising CD. Areas covered in this review: This review of the literature summarizes available data on of efficacy and safety profile adalimumab in patients with UC. What the reader will gain: Adalimumab may be effective in inducing and maintaining clinical remission in patients with moderate-to-severe UC. It may also induce mucosal healing and reduce the need for colectomy in patients with severe disease. The safety profile of the drug in UC is consistent with previous experience with this drug in CD. Take home message: Adalimumab may be effective and well tolerated in UC. Its efficacy in maintaining clinical remission needs to be confirmed in a randomized controlled trial.

Original languageEnglish
Pages (from-to)109-116
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Ulcerative Colitis
Crohn Disease
Safety
Colectomy
Inflammatory Bowel Diseases
Pharmaceutical Preparations
Anti-Idiotypic Antibodies
Randomized Controlled Trials
Monoclonal Antibodies
Adalimumab
Antibodies
Therapeutics

Keywords

  • adalimumab
  • anti-TNF-α
  • inflammatory bowel disease
  • ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Adalimumab in ulcerative colitis : Hypes and hopes. / Fiorino, Gionata; Peyrin-Biroulet, Laurent; Repici, Alessandro; Malesci, Alberto; Danese, Silvio.

In: Expert Opinion on Biological Therapy, Vol. 11, No. 1, 01.2011, p. 109-116.

Research output: Contribution to journalArticle

@article{92e792a199314c2f9ba12c9015e08d80,
title = "Adalimumab in ulcerative colitis: Hypes and hopes",
abstract = "Importance of the field: The advent of anti-TNF-α monoclonal antibodies has dramatically changed the management of inflammatory bowel diseases (IBD). Unlike Crohn's disease (CD), only one anti-TNF-α agent, infliximab, is currently approved for active moderate-to-severe ulcerative colitis (UC). Adalimumab is a fully human anti-TNF-α antibody that is effective and safe for the treatment of luminal and fistulising CD. Areas covered in this review: This review of the literature summarizes available data on of efficacy and safety profile adalimumab in patients with UC. What the reader will gain: Adalimumab may be effective in inducing and maintaining clinical remission in patients with moderate-to-severe UC. It may also induce mucosal healing and reduce the need for colectomy in patients with severe disease. The safety profile of the drug in UC is consistent with previous experience with this drug in CD. Take home message: Adalimumab may be effective and well tolerated in UC. Its efficacy in maintaining clinical remission needs to be confirmed in a randomized controlled trial.",
keywords = "adalimumab, anti-TNF-α, inflammatory bowel disease, ulcerative colitis",
author = "Gionata Fiorino and Laurent Peyrin-Biroulet and Alessandro Repici and Alberto Malesci and Silvio Danese",
year = "2011",
month = "1",
doi = "10.1517/14712598.2011.541435",
language = "English",
volume = "11",
pages = "109--116",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Adalimumab in ulcerative colitis

T2 - Hypes and hopes

AU - Fiorino, Gionata

AU - Peyrin-Biroulet, Laurent

AU - Repici, Alessandro

AU - Malesci, Alberto

AU - Danese, Silvio

PY - 2011/1

Y1 - 2011/1

N2 - Importance of the field: The advent of anti-TNF-α monoclonal antibodies has dramatically changed the management of inflammatory bowel diseases (IBD). Unlike Crohn's disease (CD), only one anti-TNF-α agent, infliximab, is currently approved for active moderate-to-severe ulcerative colitis (UC). Adalimumab is a fully human anti-TNF-α antibody that is effective and safe for the treatment of luminal and fistulising CD. Areas covered in this review: This review of the literature summarizes available data on of efficacy and safety profile adalimumab in patients with UC. What the reader will gain: Adalimumab may be effective in inducing and maintaining clinical remission in patients with moderate-to-severe UC. It may also induce mucosal healing and reduce the need for colectomy in patients with severe disease. The safety profile of the drug in UC is consistent with previous experience with this drug in CD. Take home message: Adalimumab may be effective and well tolerated in UC. Its efficacy in maintaining clinical remission needs to be confirmed in a randomized controlled trial.

AB - Importance of the field: The advent of anti-TNF-α monoclonal antibodies has dramatically changed the management of inflammatory bowel diseases (IBD). Unlike Crohn's disease (CD), only one anti-TNF-α agent, infliximab, is currently approved for active moderate-to-severe ulcerative colitis (UC). Adalimumab is a fully human anti-TNF-α antibody that is effective and safe for the treatment of luminal and fistulising CD. Areas covered in this review: This review of the literature summarizes available data on of efficacy and safety profile adalimumab in patients with UC. What the reader will gain: Adalimumab may be effective in inducing and maintaining clinical remission in patients with moderate-to-severe UC. It may also induce mucosal healing and reduce the need for colectomy in patients with severe disease. The safety profile of the drug in UC is consistent with previous experience with this drug in CD. Take home message: Adalimumab may be effective and well tolerated in UC. Its efficacy in maintaining clinical remission needs to be confirmed in a randomized controlled trial.

KW - adalimumab

KW - anti-TNF-α

KW - inflammatory bowel disease

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=78650050173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650050173&partnerID=8YFLogxK

U2 - 10.1517/14712598.2011.541435

DO - 10.1517/14712598.2011.541435

M3 - Article

C2 - 21133817

AN - SCOPUS:78650050173

VL - 11

SP - 109

EP - 116

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -